BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31814621)

  • 1. Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients.
    Bhagirath D; Dahiya R; Majid S; Tabatabai ZL; Saini S
    J Vis Exp; 2019 Nov; (153):. PubMed ID: 31814621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
    Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
    Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular model for neuroendocrine prostate cancer progression.
    Chen R; Dong X; Gleave M
    BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of MicroRNAs in Neuroendocrine Prostate Cancer.
    Sreekumar A; Saini S
    Noncoding RNA; 2022 Mar; 8(2):. PubMed ID: 35447888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients.
    Bhagirath D; Liston M; Akoto T; Lui B; Bensing BA; Sharma A; Saini S
    Sci Rep; 2021 Apr; 11(1):8279. PubMed ID: 33859239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
    Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
    Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
    Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance.
    Hu CY; Wu KY; Lin TY; Chen CC
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of actinin-4 (ACTN4) in exosomes as a potential novel therapeutic target in castration-resistant prostate cancer.
    Ishizuya Y; Uemura M; Narumi R; Tomiyama E; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Imamura R; Adachi J; Tomonaga T; Nonomura N
    Biochem Biophys Res Commun; 2020 Mar; 523(3):588-594. PubMed ID: 31941606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer.
    Akoto T; Bhagirath D; Saini S
    Cancer Drug Resist; 2020; 3(4):804-818. PubMed ID: 33426506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism.
    Shih JW; Wang LY; Hung CL; Kung HJ; Hsieh CL
    Int J Mol Sci; 2015 Dec; 16(12):28943-78. PubMed ID: 26690121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HOTAIR is a REST-regulated lncRNA that promotes neuroendocrine differentiation in castration resistant prostate cancer.
    Chang YT; Lin TP; Tang JT; Campbell M; Luo YL; Lu SY; Yang CP; Cheng TY; Chang CH; Liu TT; Lin CH; Kung HJ; Pan CC; Chang PC
    Cancer Lett; 2018 Oct; 433():43-52. PubMed ID: 29944905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes.
    Lin LC; Gao AC; Lai CH; Hsieh JT; Lin H
    Cancer Lett; 2017 Apr; 391():74-82. PubMed ID: 28109910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
    Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
    Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosomes derived from myeloid-derived suppressor cells facilitate castration-resistant prostate cancer progression via S100A9/circMID1/miR-506-3p/MID1.
    Gao F; Xu Q; Tang Z; Zhang N; Huang Y; Li Z; Dai Y; Yu Q; Zhu J
    J Transl Med; 2022 Aug; 20(1):346. PubMed ID: 35918733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
    Li Y; Donmez N; Sahinalp C; Xie N; Wang Y; Xue H; Mo F; Beltran H; Gleave M; Wang Y; Collins C; Dong X
    Eur Urol; 2017 Jan; 71(1):68-78. PubMed ID: 27180064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.
    Zou M; Toivanen R; Mitrofanova A; Floch N; Hayati S; Sun Y; Le Magnen C; Chester D; Mostaghel EA; Califano A; Rubin MA; Shen MM; Abate-Shen C
    Cancer Discov; 2017 Jul; 7(7):736-749. PubMed ID: 28411207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
    Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
    J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.